1. Diterpene promptly executes a non-canonical autophagic cell death in doxorubicin-resistant lung cancer
- Author
-
Wei-Jun Chiu, Chun-Shu Lin, Shian-Ren Lin, Ting-Hsu Chen, Chia-Jen Wu, Prabhakar Busa, Hui Long, Ching-Cheng Chen, Feng-Jen Tseng, Yaw-Syan Fu, and Ching-Feng Weng
- Subjects
16-Hydroxycleroda-3,13-dien-15,16-olide ,Non-small cell lung carcinoma ,Autophagy ,Herbal medicine ,Doxorubicin ,Intratrachea xenograft ,Therapeutics. Pharmacology ,RM1-950 - Abstract
16-hydroxycleroda-3,13-dien-15,16-olide (HCD) has antitumor activity reported in numerous types of cancers. However, the efficacy of HCD treatment in non-small-cell lung cancer (NSCLC) cells and doxorubicin-resistant (Dox-R)-NSCLC cells remains to be unraveled. The underlying anti-cancer mechanism of HCD on Dox-R and Dox-sensitive (Dox-S) of A549 cells was also investigated. Cytotoxicity of HCD against two cell lines (Dox-S and Dox-R) were determined via MTT assay, flow cytometry, and Western blot. A further examination of its anti-cancer efficacy was performed in A549-bearing xenograft mice via orthotopic intratrachea (IT) inoculation, which showed that HCD could arrest both Dox-S and Dox-R cells at G2/M phase without altering the sub-G1 cycle along with increasing of cleaved-PARP. HCD downregulated the mTOR/Akt/PI3K-p85 and PI3K-ClassIII/Beclin-1 signals and upregulated p62/LC3-I/II expressions to further confirm that the cell autophagy of NSCLC cells after being HCD-induced. Morphological observations of mouse lung sections illustrated that fewer cancer cells accumulated close to the trachea while less neoplastic activities were found in HCD orthotopic treated mice without liver, kidney, and spleen toxicity. Lastly, Dox, HCD, and target therapy medicines of EGFR and ALK were nicely docked with EGFR, ALK, and mTOR. Conclusively, HCD was demonstrated the chemotherapeutic potential regardless of Dox-R and Dox-S cells, suggesting natural autophagic inducer HCD provides a promising lead compound for new drug discovery and development of lung cancer therapies.
- Published
- 2022
- Full Text
- View/download PDF